Clinical Trial

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated April 21, 2025 completion). Its status may not reflect the trial's current state.
Summary
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-17; most recent amendment 2024-08-27.
Status change: Not Yet Recruiting → Recruiting 2024-08-25
Trial Details
NCT Number NCT06379646
Lead Sponsor China Immunotech (Beijing) Biotechnology Co., Ltd.
Collaborators: Shanghai Changzheng Hospital
Conditions Systemic Lupus Erythematosus, Systemic Sclerosis, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antiphospholipid Syndrome, Sjogren's Syndrome
Enrollment 6 participants
Start Date 2024-04-24
Primary Completion 2025-04-21 (estimated)
Study Completion 2026-04-21 (estimated)
Updated on ClinicalTrials.gov 2024-08-29